ArticleFrontiers in oncology2026
Glucagon-like peptide-1 receptor (GLP-1R) overexpression defines a distinct immunogenetic subset in primary and metastatic thyroid cancer: implications for GLP-1R agonist therapy.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The surge in prescribing glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for diabetes and weight management highlights a pressing need to characterize their associated risks. All GLP-1 RAs include an FDA boxed warning for increased risk of development of medullary thyroid carcinoma (MTC) based on early murine studies. However, clinical evidence remains conflicting and highly debated, highlighting the importance of comprehensively characterizing GLP-1R expression in both primary and metastatic thyroid cancers. Methods: We leveraged transcriptomic data from The Cancer Genome Atlas (TCGA) from 11,160 patients across 33 cancer types to comparatively analyze GLP-1R transcriptomic expression across normal, primary, and metastatic tissues. We also performed flow cytometric analysis on primary and metastatic medullary and papillary thyroid carcinomas (PCT) to quantify differential GLP-1R protein expression levels. Results: Strikingly, metastatic PTC displayed the highest median GLP-1R mRNA expression among all TCGA cancers. This finding was supported by flow cytometry of patient tumor samples, which confirmed elevated GLP-1R protein expression in both PTC and MTC metastatic tissues as compared to their respective primary tumors. Further, GLP-1R expression levels stratified TCGA thyroid cancers into unique immunogenetic transcriptional profiles. Tumors with high GLP-1R expression were notably associated with downregulated immune pathway activity and decreased immune cell infiltration. Discussion: These findings identify a subset of thyroid carcinomas with high GLP-1R expression, most pronounced in metastatic disease, which are accompanied by distinct genetic and immunological profiles. As GLP-1R agonist therapies continue to expand in clinical use, further investigation is warranted to determine the oncogenic implications of this overexpression for thyroid cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.